Also, it is known that 20% of MASLD patients progress to the MASH stage with chronic inflammation and fibrosis, which can lead to cirrhosis and HCC, with TREM2+ macrophages playing a crucial role in this process. The gene discussed is TREM2; the disease is metabolic dysfunction-associated steatotic liver disease.